Cite
HARVARD Citation
Tamburini, E. et al. (n.d.). 2109 Anti-EGFR or Bevacizumab in first line treatment of RAS wild type metastatic colorectal neoplasm (RwtMCRC): pooled analysis of randomized clincal trials. European journal of cancer. pp. S365-. [Online].